Abstract
Postmenopausal osteoporosis affects millions of women each year. Initial treatment is based on many factors including T-score, fracture risk assessment tool score, and risk factors for fractures. The most recent additions to treatment are aimed at those who are considered to be at higher fracture risk. The newest FDA-approved medications, abaloparatide and romosozumab, work to increase bone formation in 18 and 12 months, respectively. Abaloparatide has shown a statistically significant effect in preventing vertebral fractures compared with placebo. Studies using romosozumab have shown significantly increased bone mineral density compared with teriparatide.